Business

PDMR Dealing

Oxford Biomedica plc announced that Chief People Officer Lisa Doman and Chief Innovation Officer Kyriacos Mitrophanous each exercised 3,057 SAYE 2022 options at £2.944 per share on December 8, 2025, and subsequently sold their respective 3,057 ordinary shares at an average price of £6.23026 per share, resulting in a total sale value of £19,045.90 for each individual. Disclaimer*

articleOxford Biomedica PlcDecember 8, 20253/company/oxford-biomedica-plc/news/pdmr-dealing-44
PDMR Dealing

About this update from Oxford Biomedica Plc

[{"type":"text","content":"\n\n \nPDMR Dealing\nOxford, UK - 08 December 2025: OXB (LSE: OXB) (the \"Company\"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Lisa Doman, Chief People Officer and Kyriacos Mitrophanous, Chief Innovation Officer have exercised their respective 3,057 SAYE 2022 options at an exercise price of £2.944 on 08 December 2025 and disposed of their respective 3,057 shares at an average price of £6.23026 per share on 08 December 2025.\nThe below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.\n \n\n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n\n\n\n\na)\n\n\nName\n\n\nLisa Doman\n\n\n\n\n2.\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nPerson Discharging Managerial Responsibility\n\n\n\n\nb)\n\n\nInitial notification/ amendment\n\n\nInitial Notification\n\n\n\n\n3.\n\n\nDetails of the Issuer\n\n\n\n\na)\n\n\nFull name of the entity\n\n\nOxford Biomedica plc\n\n\n\n\nb)\n\n\nLEI code\n\n\n213800S1GVQNXQ15K851\n\n\n\n\n4.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDate of the transaction\n\n\n2025-12-08\n\n\n\n\nb)\n\n\nDescription of the financial instrument\n\n\nSAYE Options over Ordinary Shares of 50 pence each\n \n\n\n\n\nc)\n\n\nIdentification code\n\n\nISIN: GB00BDFBVT43\n\n\n\n\nd)\n\n\nNature of the transaction\n\n\nExercise of SAYE 2022 Options at £2.944\n\n\n\n\ne)\n\n\nPlace of the transaction\n\n\nOutside the trading venue\n\n\n\n\nf)\n\n\nCurrency\n\n\nGBP - British pound\n\n\n\n\ng)\n\n\nPrice(s) and volumes(s)\n \n\n\n\n\n\n\nPrice(s)\n\n\nVolume(s)\n\n\n\n\n£2.944\n\n\n3,057\n\n\n\n\n\n\n\n\n\nh)\n\n\nAggregated information\n-    Aggregate volume\n-    Price\n-    Aggregated total\n\n\n \n3,057\n£2.944\n£8999.81\n\n\n\n\n \n \n\n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n\n\n\n\na)\n\n\nName\n\n\nLisa Doman\n\n\n\n\n2.\n\n\nReason for the notificatio...

More updates from Oxford Biomedica Plc